PAICS Antibody

What is PAICS and why is it significant in cancer research?

PAICS is a bifunctional enzyme involved in the de novo purine biosynthetic pathway. It has gained attention as a potential cancer biomarker and therapeutic target because it is overexpressed in various cancer types where it contributes to:

• Cell proliferation and invasion

• Epithelial-mesenchymal transition

• Efficient tumor growth

The enzyme possesses dual activities: 5-aminoimidazole ribonucleotide carboxylase (AIRc) and 4-(N-succinylcarboxamide)-5-aminoimidazole ribonucleotide synthetase (SAICARs) . This bifunctionality makes it an attractive target for rational anticancer drug design, particularly because rapidly dividing cancer cells rely heavily on the purine de novo pathway for adenine and guanine synthesis, whereas normal cells preferentially use the salvage pathway .

What antibody options are available for PAICS detection?

Several types of antibodies are available for PAICS detection in research settings:

When selecting a PAICS antibody, researchers should consider their specific applications, target species, and detection methods to ensure optimal experimental outcomes .

What are the standard applications for PAICS antibodies?

PAICS antibodies have been validated for multiple experimental techniques:

• Western Blotting: The most widely used application, with PAICS typically detected at approximately 47 kDa . Recommended dilutions range from 1:1000 to 1:8000 depending on the antibody .

• Immunohistochemistry (IHC): Useful for detecting PAICS expression in tissue samples, particularly in cancer tissues. Typical dilutions range from 1:50 to 1:500 . Some antibodies have been specifically validated on human liver and testis tissues .

• Immunoprecipitation (IP): Valuable for studying protein-protein interactions involving PAICS. The rat monoclonal antibody 6A10 has been specifically validated for this application .

• Flow Cytometry: Some antibodies have been validated for intracellular detection of PAICS, typically using 0.25 μg per 10^6 cells in a 100 μl suspension .

• Immunofluorescence (IF): Useful for studying subcellular localization of PAICS .

How does species cross-reactivity affect PAICS antibody selection for comparative studies?

Understanding species cross-reactivity is critical when designing comparative studies:

• The rat monoclonal antibody 6A10 recognizes human, monkey, and dog PAICS but does not detect rat or mouse PAICS due to sequence differences in the N-terminal antigenic region . This makes it unsuitable for mouse model comparisons but excellent for primate studies.

• Rabbit polyclonal antibodies like 12967-1-AP and HPA035895 show broader cross-reactivity, recognizing human, mouse, and sometimes rat PAICS . This makes them valuable for translational research involving rodent models.

When selecting antibodies for comparative studies across species, researchers should:

• Verify sequence homology in the antigenic region

• Perform appropriate validation in each target species

• Consider using multiple antibodies targeting different epitopes for confirmation

What are optimal protocols for using PAICS antibodies in western blotting?

For optimal western blotting results with PAICS antibodies:

• Sample Preparation:

  • Multiple cancer cell lines have been validated for PAICS detection, including HL-60, HeLa, Jurkat, K-562, Raji, and THP-1 cells

  • Mouse heart and brain tissues also express detectable PAICS levels

• Antibody Selection and Dilution:

  • For mouse monoclonal OTI5B6: 1:1000 dilution is recommended

  • For rabbit polyclonal 12967-1-AP: 1:1000-1:8000 dilution range, with optimization recommended for each cell line

  • For rabbit polyclonal HPA035895: 0.04-0.4 μg/mL concentration is effective

• Detection:

  • PAICS typically appears as a 47 kDa band

  • Multiple isoforms may be detected in some samples, with up to 2 different isoforms reported for this protein

• Controls:

  • Positive controls: Raji cells are consistently mentioned as reliable positive controls

  • Negative controls: Consider PAICS knockout samples or cell lines with low expression

What methodological considerations apply to immunohistochemistry with PAICS antibodies?

For optimal IHC results with PAICS antibodies:

• Tissue Preparation:

  • Formalin-fixed paraffin-embedded (FFPE) tissues are compatible with most PAICS antibodies

  • Fresh-frozen tissues may provide better epitope preservation for certain antibodies

• Antigen Retrieval:

  • TE buffer pH 9.0 is suggested for optimal antigen retrieval

  • Alternative approach: citrate buffer pH 6.0

• Antibody Dilution and Incubation:

  • For rabbit polyclonal 12967-1-AP: 1:50-1:500 dilution range

  • For rabbit polyclonal HPA035895: 1:50-1:200 dilution range

  • Optimization is recommended for each tissue type and fixation method

• Validated Tissues:

  • Human liver and testis tissues have been specifically validated for PAICS detection

  • Cancer tissues often show higher expression levels compared to normal tissues

• Methodological Papers:

  • Review optimization protocols described in "Optimization of protocols for immunohistochemical assessment of enteric nervous system in formalin fixed human tissue" for general IHC guidance

How can researchers effectively use PAICS antibodies for studying cancer mechanisms?

PAICS antibodies have been instrumental in elucidating cancer mechanisms:

• Knockdown/Knockout Studies:

  • PAICS antibodies can confirm effective knockdown in functional studies examining cancer phenotypes

  • Published studies include "Knockdown of PAICS inhibits malignant proliferation of human breast cancer cell lines"

• Cancer Biomarker Analysis:

  • IHC with PAICS antibodies has been used to evaluate PAICS as a prognostic marker in lung adenocarcinoma

  • The correlation between PAICS expression and clinical outcomes can be assessed using standardized scoring systems

• Therapeutic Target Validation:

  • PAICS has been identified as a potential therapeutic target for EGFR wild-type non-small cell lung cancer through CRISPR-Cas9 screening

  • Antibodies can validate target engagement of novel inhibitors

• Purinosome Formation Studies:

  • PAICS antibodies have been used to study purinosome formation in neuronal differentiation and migration

  • Co-localization studies with other purine synthesis enzymes can reveal functional complexes

How do recent advancements in antibody development impact PAICS research?

Recent technological advances are transforming antibody development:

• Deep Learning Approaches:

  • Generative adversarial networks (GANs) and Wasserstein GANs with Gradient Penalty (WGAN+GP) are enabling in silico design of antibodies with desired properties

  • These computational approaches can potentially generate PAICS-targeting antibodies with optimized specificity and developability

• Experimental Validation of Computationally-Designed Antibodies:

  • In silico generated antibodies are being validated by independent laboratories for expression, monomer content, thermal stability, hydrophobicity, self-association, and binding properties

  • This approach could accelerate the development of next-generation PAICS antibodies

• Advantages for Target Expansion:

  • Computational approaches may enable antibody development against targets refractory to conventional discovery methods that require in vitro antigen production

  • This could facilitate antibodies against challenging PAICS epitopes or conformational states

• Medicine-Likeness Optimization:

  • Deep learning models can generate antibodies with physicochemical properties resembling marketed antibody therapeutics

  • This approach could yield PAICS antibodies with improved developability profiles for both research and potential therapeutic applications

How can researchers address non-specific binding with PAICS antibodies?

Non-specific binding can compromise experimental results. Researchers should consider:

• Antibody Validation:

  • Verify antibody specificity using positive and negative controls

  • Consider PAICS knockout or knockdown samples as negative controls

  • Check for cross-reactivity with related proteins in the purine biosynthesis pathway

• Blocking Optimization:

  • For western blotting: Test different blocking agents (BSA, non-fat milk, commercial blockers)

  • For IHC/IF: Consider species-matched serum for blocking or commercial blockers

  • Optimize blocking time and temperature

• Dilution Optimization:

  • Titrate antibody concentrations to find optimal signal-to-noise ratio

  • For rabbit polyclonal 12967-1-AP, the recommended range is wide (1:1000-1:8000 for WB)

  • Lower concentrations may reduce background but require more sensitive detection systems

• Sample-Specific Considerations:

  • Certain tissue/cell types may require specific protocol modifications

  • Consider additional washing steps or detergent concentration adjustments

What are the best practices for validating novel findings with PAICS antibodies?

Rigorous validation is essential when reporting novel PAICS findings:

• Multiple Antibody Approach:

  • Confirm key findings using at least two different antibodies targeting different PAICS epitopes

  • Compare results from monoclonal and polyclonal antibodies when possible

• Complementary Techniques:

  • Validate protein-level findings with mRNA-level analysis

  • Consider mass spectrometry validation for protein identification

  • Use genetic approaches (siRNA, CRISPR) to confirm antibody specificity

• Species Considerations:

  • Be aware of species-specific limitations (e.g., rat mAb 6A10 doesn't recognize mouse/rat PAICS)

  • Document species cross-reactivity when reporting novel findings

• Reproducibility Measures:

  • Include detailed methodological information for antibody use

  • Report antibody catalog numbers, dilutions, incubation conditions

  • Consider providing raw data and images in supplementary materials

How might PAICS antibodies contribute to emerging cancer therapeutics?

PAICS antibodies are poised to impact cancer therapeutic development:

• Companion Diagnostics:

  • PAICS antibodies could serve as companion diagnostics for emerging purine metabolism inhibitors

  • IHC with validated antibodies may help stratify patients for clinical trials

• Therapeutic Targeting:

  • While direct antibody therapeutics targeting intracellular PAICS are challenging, antibodies remain crucial tools for validating small molecule inhibitors

  • PAICS antibodies can confirm on-target effects in preclinical studies

• Biomarker Development:

  • Studies suggest PAICS may serve as a biomarker for malignant transformation

  • Standardized IHC protocols with validated antibodies will be essential for clinical implementation

• Combination Therapy Research:

  • PAICS antibodies can help identify synergistic pathways for combination therapy

  • Monitor PAICS expression changes in response to other treatments to identify potential resistance mechanisms

What technical innovations might improve PAICS antibody performance?

Emerging technologies may enhance PAICS antibody applications:

• Recombinant Antibody Technology:

  • Moving from hybridoma-derived antibodies to recombinant formats could improve consistency

  • Site-specific modifications could enhance performance for specific applications

• Multiplexing Capabilities:

  • Development of PAICS antibodies compatible with multiplexed imaging techniques

  • Integration with spatial transcriptomics for correlative analyses

• Advanced Conjugation Strategies:

  • Novel conjugation approaches for improved sensitivity in detection

  • Development of internalization-capable antibody conjugates for delivering cargo to PAICS-overexpressing cells

• Computational Optimization:

  • Structure-based epitope prediction to generate antibodies against functional domains

  • Machine learning approaches to optimize antibody properties for specific applications